Effect of silica and gold nanoparticles on macrophage proliferation, activation markers, cytokine production, and phagocytosis in vitro

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 183-206

  Bancos, Simona ^a   Stevens, David L ^a   Tyner, Katherine M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bioaccumulation; Gold nanoparticles; Macrophage function; Phagocytosis; Silica nanoparticles

Indexed keywords

CELL SURFACE MARKER; CYTOKINE; GOLD NANOPARTICLE; SILICON DIOXIDE; GOLD; METAL NANOPARTICLE;

ANIMAL CELL; ARTICLE; BACTERICIDAL ACTIVITY; BIOACCUMULATION; CELL CYCLE; CELL PROLIFERATION; CELL STRUCTURE; CONFOCAL MICROSCOPY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; ANIMAL; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; MACROPHAGE; METABOLISM; RAW 264.7 CELL LINE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; GOLD; MACROPHAGES; METAL NANOPARTICLES; MICE; PARTICLE SIZE; PHAGOCYTOSIS; RAW 264.7 CELLS; SILICON DIOXIDE;

EID: 84920089786     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S72580     Document Type: Article

References (50)

1. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1):1–14.
2. Horstkotte E, Odoerfer KI. Towards improved therapies using nano-pharmaceuticals: recent patents on pharmaceutical nanoformulations. Recent Pat Food Nutr Agric. 2012;4(3):220–244.
3. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol. 2011; 165(7–8):1628–1651.
4. Hall JB, Dobrovolskaia MA, Patri AK, SMcNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine. 2007;2(6):789–803.
5. Kateb B, Chiu K, Black KL, et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage. 2011;54(suppl 1):S106–S124.
6. Benezra M, Penate-Medina O, Zanzonico PB, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011;121(7):2768–2780.
7. Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nano-medicine. Clin Cancer Res. 2010;16(24):6139–6149.
8. Demoy M, Andreux JP, Weingarten C, Gouritin B, Guilloux V, Couvreur P. Spleen capture of nanoparticles: influence of animal species and surface characteristics. Pharm Res. 1999;16(1):37–41.
9. Cho WS, Cho M, Jeong J, et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol. 2009;236(1):16–24.
10. De Jong WH, Hagens WH, Krystek P, Burger MC, Sips AJAM, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 2008;29(12):1912–1919.
11. Hirn S, Semmler-Behnke M, Schleh C, et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm. 2011;77(3):407–416.
12. Virella G. Diagnostic evaluation of phagocytic function. In: Virella G, editor. Immunology Series. Vol. 58. New York: Marcel Dekker; 1993:311–327.
13. Campbell PA, Vanono BP, Drevets DA. Measurement of bacterial ingestion and killing by macrophages. In: Collgan JE, Kruisbeck AM, Margulies DH, Shevach EM, Strober W, editors. Current Protocols in Immunology. New York: John Wiley & Sons, Inc; 1994:14.6.1–14.6.13.
14. Skoczen SL, Potter TM, Dobrovolskaia MA. In vitro analysis of nanoparticle uptake by macrophages using chemiluminescence. In: McNeil SE, editor. Characterization of Nanoparticles Intended for Drug Delivery. New York: Springer Science; 2011:255–261.
15. Braydich-Stolle LK, Speshock JL, Castle A, Smith M, Murdock RC, Hussain SM. Nanosized aluminum altered immune function. ACS Nano. 2010;4(7):3661–3670.
16. Shvedova AA, Fabisiak JP, Kisin ER, et al. Sequential exposure to carbon nanotubes and bacteria enhances pulmonary infammation and infectivity. Am J Respir Cell Mol Biol. 2008;38(5):579–590.
17. Mitchell LA, Lauer FT, Burchiel SW, McDonald JD. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat Nanotechnol. 2009;4(7):451–456.
18. Zogovic NS, Nikolic NS, Vranjes-Djuric SD, et al. Opposite effects of nanocrystalline fullerene (C(60)) on tumour cell growth in vitro and in vivo and a possible role of immunosupression in the cancer-promoting activity of C(60). Biomaterials. 2009;30(36):6940–6946.
19. Moon EY, Yi GH, Kang JS, Lim JS, Kim HM, Pyo S. An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide nanoparticles. J Immunotoxicol. 2011;8(1):56–67.
20. Guidance for Industry. S8 Immunotoxicity Studies for Human Pharmaceuticals; 2006. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm074965.pdf
21. Bancos S, Weaver JL, Katherine Tyner KM. Evaluation of viability and proliferation profiles of macrophage-treated silica nanoparticles in vitro via plate based, flow cytometry and Coulter counter assays. ISRN Nanotechnol. 2012(2012); Article ID 454072:11.
22. Keene AM, Tyner KM. Analytical characterization of gold nanoparticle primary particles, aggregates, agglomerates, and agglomerated aggregates. J Nanopart Res. 2011;13:3465–3481.
23. Keene AM, Peters D, Rouse R, Stewart S, Rosen ET, Tyner KM. Tissue and cellular distribution of gold nanoparticles varies based on aggregation/ agglomeration status. Nanomedicine. 2012;7(2):199–209.
24. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC, USA: National Academy Press; 1996.
25. Thakor AS, Luong R, Paulmurugan R, et al. The fate and toxicity of Raman-active silica-gold nanoparticles in mice. Sci Transl Med. 2011; 3(79):79ra33.
26. Goel R, Shah N, Visaria R, Paciotti GF, Bischof JC. Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. Nanomedicine. 2009;4(4):401–410.
27. Mukherjee P. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005;11:3530–3534.
28. Warheit DB. How meaningful are the results of nanotoxicity studies in the absence of adequate material characterization. Toxicol Sci. 2008; 101(2):183–185.
29. Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med. 2009;267(1):89–105.
30. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci. 2006;95(2):300–312.
31. Ulevitch RJ, Tobias PS. Receptor dependent mechanism of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995;13:437–457.
32. Lichtman SN, Wang J, Lemasters JJ. LPS receptor CD14 participates in release of TNF-α in RAW 264.7 and peritoneal cells but not in Kupffer cells. Am J Physiol. 1998;275(1):G39–G46.
33. Netea MG, Kullberg BJ, van der Meer J W. Lipopolysaccharide-induced production of tumor necrosis factor and interleukin-1 is differentially regulated at the receptor level: the role of CD-14-dependent and CD-14-independent pathways. Immunology. 1998;94(3):340–343.
34. Jian ZJ, Yang Z, Miller MS, Carter CD, Slauson DO, Bochsler PN. Interleukin-6 secretion by bacterial lipopolysaccharide-stimulated bovine alveolar macrophages in vitro. Vet Immunol Immunopathol. 1995;49(1–2):51–60.
35. Zhang Q, Hitchins VM, Schrand AM, Hussain SM, Goering P. Uptake of gold nanoparticles in murine macrophage cells without cytotoxicity or production of pro-infammatory mediators. Nanotoxicology. 2011;5(3):284–295.
36. Kusaka T, Nakayama M, Nakamura K, Ishimiya M, Furusawa E, Ogasawara K. Effect of silica particle size on macrophage inflammatory responses. PLoS One. 2014;9(3):e92634.
37. Gosens I, Post JA, de la Fonteyne LJJ, et al. Impact of agglomeration state of nano- and submicron sized gold particles on pulmonary inflammation. Part Fibre Toxicol. 2010;7(37):1–11.
38. Lee JY, Park W, Yi DK. Immunostimulatory effects of gold nanorod and silica-coated gold nanorod on RAW 264.7 mouse macrophages. Toxicol Lett. 2012;209(1):51–57.
39. Kim S, Oh WK, Jeong YS, et al. Cytotoxicity of, and innate immune response to, size-controlled polypyrrole nanoparticles in mammalian cells. Biomaterials. 2011;32(9):2234–2250.
40. Kim JS, Adamcakova-Dodd A, O’Shaughnessy PT, Grassian VH, Thorne PS. Effects of copper nanoparticle exposure on host defense in a murine pulmonary infection model. Part Fibre Toxicol. 2011; 8:29–43.
41. Deicher R, Xiai F, Cohen G, Mullner M, Horl WH. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int. 2003;64:728–736.
42. Danikas KK, Karakantza M, Theodorous GL, Sakellaropoulos GC, Gogos CA. Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression. Clin Exp Immunol. 2008;154(1):87–97.
43. Prieto J, Subira ML, Vastilla A, Civeira MP, Serrano M. Monocyte disorder causing cellular immunodefciency: a family study. Clin Exp Immunol. 1990;79(1):1–6.
44. Wolach B, Gavrieli R, Roos D, Berger-Achituv S. Lessons learned from phagocytic function studies in a large cohort of patients with recurrent infections. J Clin Immunol. 2012;32(3):454–466.
45. Sharbaugh RJ. Effect of cyclophosphamide on in vitro phagocytosis of staphylococcus aureus. J Infect Dis. 1976;134(6):619–623.
46. Coraschi D, Constantino L, Italiani P. Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. Nanomedicine. 2012;7(12):121–131.
47. Qu G, Zhang C, Yuan L, et al. Quantum dots impair macrophagic morphology and the ability of phagocytosis by inhibiting the Rho-associated kinase signaling. Nanoscale. 2012;4:2239–2244.
48. Renwick LC, Brown D, Clouter A, Donaldson K. Increased infammation and altered macrophage chemotactic responses caused by two ultrafne particle types. Occup Environ Med. 2004;61(5):442–447.
49. Liu H, Yang D, Yang H, et al. Comparative study of respiratory tract immune toxicity induced by three sterilisation nanoparticles: silver, zinc oxide and titanium dioxide. J Hazard Mater. 2013;248–249:478–486.
50. Kodali V, Littke MH, Tilton SC, et al. Dysregulation of macrophage activation profiles by engineered nanoparticles. ACS Nano. 2013;7(8): 6997–7010.